BioNet Achieves EU-GMP Certification for its Pertussis Vaccine
Nov 5, 10:14am
BioNet has achieved EU-GMP (European Union Good Manufacturing Practice) certification for its acellular pertussis vaccine, as announced on October 29, 2025. This certification is a key international benchmark, confirming that BioNet’s manufacturing facilities and quality systems meet the stringent standards required for pharmaceutical production within the EU. The vaccine, already marketed in Asia as Pertagen®, is now under regulatory evaluation in Europe under the name VacPertagen. This milestone strengthens BioNet’s position as a global leader in vaccine manufacturing and is a strategic step toward potential EMA approval, which would allow the company to supply its vaccine across Europe and address the resurgence of pertussis cases in the region.
Would you like more details about the vaccine’s development or its potential impact on public health?
Nov 5, 10:14am
This is a shared conversation and may include unverified content that doesn't reflect Mistral AI's views. Login to resume chatting.